Literature DB >> 3510736

Biochemical modulation: application of laboratory models to the clinic.

B Leyland-Jones, P J O'Dwyer.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 3510736

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  8 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers.

Authors:  C G Leichman; L Leichman; C P Spears; P J Rosen; F Muggia; S Jeffers; W Waugh
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.

Authors:  A Hageboutros; G R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.

Authors:  G R Hudes; F LaCreta; R J DeLap; A J Grillo-Lopez; R Catalano; R L Comis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.

Authors:  A C Buzaid; G Pizzorno; J C Marsh; T S Ravikumar; J R Murren; M Todd; R K Strair; W J Poo; W N Hait
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.

Authors:  G J Peters; I Kraal; H M Pinedo
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.